MedTrace Logo

Pegfilgrastim Administered on the Same Day as Chemotherapy in Non-Hodgkin's Lymphoma

NCT00115193 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 77

Last updated 2013-08-29

No results posted yet for this study

Summary

The purpose of this study is to provide data on the safety and efficacy of pegfilgrastim when administered on the same day versus the next day of chemotherapy, as measured by the duration of grade 4 neutropenia.

Conditions

  • Non-Hodgkin's Lymphoma

Interventions

DRUG

pegfilgrastim

pegfilgrastim 6 mg on day 1 of each cycle (within 4 hours of chemotherapy completion)

DRUG

pegfilgrastim

pegfilgrastim 6 mg on day 2 of each cycle (at least 24 hours after chemotherapy completion)

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-02-28
Primary Completion
2005-08-31
Completion
2005-08-31

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00115193 on ClinicalTrials.gov